![](/images/graphics-bg.png)
Bone-Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer : Evolving Paradigms
Joint Authors
Aragon-Ching, Jeanny B.
Patel, Nihar
Freeman, Ashley
El-Amm, Joelle
Source
Issue
Vol. 2013, Issue 2013 (31 Dec. 2013), pp.1-10, 10 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2013-08-28
Country of Publication
Egypt
No. of Pages
10
Main Subjects
Abstract EN
Majority of patients with metastatic castrate resistant prostate cancer (mCRPC) develop bone metastases which results in significant morbidity and mortality as a result of skeletal-related events (SREs).
Several bone-targeted agents are either in clinical use or in development for prevention of SREs.
Bisphosphonates were the first class of drugs investigated for prevention of SREs and zoledronic acid is the only bisphosphonate that is FDA-approved for this indication.
Another bone-targeted agent is denosumab which is a fully humanized monoclonal antibody that binds to the RANK-L thereby inhibiting RANK-L mediated bone resorption.
While several radiopharmaceuticals were approved for pain palliation in mCRPC including strontium and samarium, alpharadin is the first radiopharmaceutical to show significant overall survival benefit.
Contemporary therapeutic options including enzalutamide and abiraterone have effects on pain palliation and SREs as well.
Other novel bone-targeted agents are currently in development, including the receptor tyrosine kinase inhibitors cabozantinib and dasatinib.
Emerging therapeutics in mCRPC has resulted in great strides in preventing one of the most significant sources of complications of bone metastases.
American Psychological Association (APA)
El-Amm, Joelle& Freeman, Ashley& Patel, Nihar& Aragon-Ching, Jeanny B.. 2013. Bone-Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer : Evolving Paradigms. Prostate Cancer،Vol. 2013, no. 2013, pp.1-10.
https://search.emarefa.net/detail/BIM-454863
Modern Language Association (MLA)
El-Amm, Joelle…[et al.]. Bone-Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer : Evolving Paradigms. Prostate Cancer No. 2013 (2013), pp.1-10.
https://search.emarefa.net/detail/BIM-454863
American Medical Association (AMA)
El-Amm, Joelle& Freeman, Ashley& Patel, Nihar& Aragon-Ching, Jeanny B.. Bone-Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer : Evolving Paradigms. Prostate Cancer. 2013. Vol. 2013, no. 2013, pp.1-10.
https://search.emarefa.net/detail/BIM-454863
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-454863